A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : mGlu5 / metabotropic glutamate 5

[Related PubMed/MEDLINE]
Total Number of Papers: 73
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   mGlu5  (>> Co-occurring Abbreviation)
Long Form:   metabotropic glutamate 5
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 D1-mGlu5 heteromers mediate noncanonical dopamine signaling in Parkinson's disease. ---
2020 Detailed In Vitro Pharmacological Characterization of Clinically Tested Negative Allosteric Modulators of the Metabotropic Glutamate Receptor 5. NAMs
2020 Development and validation of a mass spectrometry binding assay for mGlu5 receptor. LC-ESI-MS/MS, MS, NAM
2020 Striatal and cortical metabotropic glutamate 5 receptor expression and behavioral effects of the positive allosteric modulator CDPPB in a model of DYT1 dystonia. CDPPB, IHC, KI
2020 Structure-based discovery and development of metabotropic glutamate receptor 5 negative allosteric modulators. CNS, GPCRs, mGlu, SBDD
2019 An Appraisal of the Influence of the Metabotropic Glutamate 5 (mGlu5) Receptor on Sociability and Anxiety. MTEP, WT
2019 Expression of metabotropic glutamate 5 receptors in the striatum and cortex and effects of modulators on the severity of dystonia in the phenotypic dtsz model. CDPPB
2019 Mechanisms Underlying Allosteric Molecular Switches of Metabotropic Glutamate Receptor 5. GPCR, MD, NAM, PAM
2019 Optical Modulation of Metabotropic Glutamate Receptor Type 5 In Vivo Using a Photoactive Drug. GPCRs, NAMs
10  2019 Radiosynthesis of the diastereomerically pure (E)-[11 C]ABP688. de, PET, RCP, RCY
11  2019 Reversible silencing of endogenous receptors in intact brain tissue using 2-photon pharmacology. ---
12  2019 Sex differences in [11C]ABP688 binding: a positron emission tomography study of mGlu5 receptors. PET
13  2018 ADX-47273, a mGlu5 receptor positive allosteric modulator, attenuates deficits in cognitive flexibility induced by withdrawal from 'binge-like' ethanol exposure in rats. NMDA, PAM
14  2018 Effects of the Positive Allosteric Modulator of Metabotropic Glutamate Receptor 5, VU-29, on Impairment of Novel Object Recognition Induced by Acute Ethanol and Ethanol Withdrawal in Rats. NOR
15  2017 A double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]-basimglurant and absolute bioavailability after oral administration and concomitant intravenous microdose administration of [13C6]-labeled basimglurant in humans. ADME, MDD
16  2017 Discovery of 4-amino-3-arylsulfoquinolines, a novel non-acetylenic chemotype of metabotropic glutamate 5 (mGlu5) receptor negative allosteric modulators. ---
17  2017 Optical control of pain in vivo with a photoactive mGlu5 receptor negative allosteric modulator. LED
18  2017 Targeting glutamatergic and cellular prion protein mechanisms of amyloid beta-mediated persistent synaptic plasticity disruption: Longitudinal studies. GOT, LTP, PrP
19  2016 2-Methyl-6-(phenylethynyl)pyridine Hydrochloride Modulates Metabotropic Glutamate 5 Receptors Endogenously Expressed in Zebrafish Brain. AD
20  2016 Brain alpha7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients. LID, MPEP, MPTP, nACh, PD
21  2016 The metabotropic glutamate 5 receptor is necessary for extinction of cocaine-associated cues. CET, CS
22  2015 Contribution of brain serotonin subtype 1B receptors in levodopa-induced motor complications. LID, MPEP, MPTP
23  2015 DSR-98776, a novel selective mGlu5 receptor negative allosteric modulator with potent antidepressant and antimanic activity. MPEP
24  2015 Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys. L-DOPA, MPEP, MPTP, PD
25  2015 Involvement of serotonergic system in the effect of a metabotropic glutamate 5 receptor antagonist in the novelty-suppressed feeding test. AMPA, MPEP, NBQX, NSF, PCPA
26  2014 Inhibitory effect of spinal mGlu(5) receptor antisense oligonucleotide on the up-regulated expression of spinal G protein associated with chronic morphine treatment. ODN
27  2014 Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys. l-DOPA, MPEP, MPTP, PD
28  2014 Pharmacological Treatments Inhibiting Levodopa-Induced Dyskinesias in MPTP-Lesioned Monkeys: Brain Glutamate Biochemical Correlates. AMPA, l-DOPA, MPTP, NMDA, PD
29  2014 Prolonged administration of antidepressant drugs leads to increased binding of [(3)H]MPEP to mGlu5 receptors. NAMs
30  2014 The mGlu5 receptor regulates extinction of cocaine-driven behaviours. ---
31  2013 Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys. L-DOPA, MPEP, MPTP, PD
32  2013 Dihydrothiazolopyridone derivatives as a novel family of positive allosteric modulators of the metabotropic glutamate 5 (mGlu5) receptor. DMPK, HTS, PAMs, SAR and SPR
33  2013 Effect of metabotropic glutamate 5 receptor antagonists on morphine efficacy and tolerance in rats with neuropathic pain. MPEP, MTEP, SNL
34  2012 Acute and sustained effects of a metabotropic glutamate 5 receptor antagonist in the novelty-suppressed feeding test. MPEP, mTOR, NSF
35  2012 Dopamine D(2) Antagonist-Induced Striatal Nur77 Expression Requires Activation of mGlu5 Receptors by Cortical Afferents. ---
36  2012 Involvement of metabotropic glutamate receptor 5 in brain reward deficits associated with cocaine and nicotine withdrawal and somatic signs of nicotine withdrawal. ICSS
37  2012 mGlu5 and adenosine A2A receptor interactions regulate the conditioned effects of cocaine. CPP, MTEP
38  2011 Effects of CNQX and MPEP on sensitization to the rewarding effects of morphine. AMPA, CNQX, CPP, MPEP
39  2010 Cocaine-mediated synaptic potentiation is absent in VTA neurons from mGlu5-deficient mice. EPSC, VTA
40  2010 Physical and crystallographic characterisation of the mGlu5 antagonist MTEP and its monohydrochloride. MTEP
41  2009 Interoceptive effects of alcohol require mGlu5 receptor activity in the nucleus accumbens. mGlu, MPEP
42  2009 Pharmacological characterization of harmaline-induced tremor activity in mice. a,d, AMPA, d-CPPene, GABA, GHB, MPEP, NBQX, NMDA
43  2008 Activated nuclear metabotropic glutamate receptor mGlu5 couples to nuclear Gq/11 proteins to generate inositol 1,4,5-trisphosphate-mediated nuclear Ca2+ release. PI, PLC
44  2008 Activation of metabotropic glutamate 5 (mGlu5) receptors induces spontaneous excitatory synaptic currents in layer V pyramidal cells of the rat prefrontal cortex. DHPG, mGlu, mPFC
45  2008 Interaction of N-methyl-D-aspartate and group 5 metabotropic glutamate receptors on behavioral flexibility using a novel operant set-shift paradigm. NMDA
46  2008 The influence of various glutamate receptors antagonists on anxiety-like effect of ethanol withdrawal in a plus-maze test in rats. NMDA
47  2007 Assessing appetitive and consummatory phases of ethanol self-administration in C57BL/6J mice under operant conditions: regulation by mGlu5 receptor antagonism. MTEP
48  2007 Blockade of metabotropic glutamate receptor 5 activation inhibits mechanical hypersensitivity following abdominal surgery. MPEP
49  2007 Different effects of ionotropic and metabotropic glutamate receptor antagonists on attention and the attentional properties of nicotine. NMDA
50  2007 mGlu5 receptor and protein kinase C implicated in the development and induction of neuropathic pain following chronic ethanol consumption. MPEP, PKC
51  2007 Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-Methyl-D-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex. CDPPB, mPFC, NAc, NMDA, PFC
52  2006 Bursting of prefrontal cortex neurons in awake rats is regulated by metabotropic glutamate 5 (mGlu5) receptors: rate-dependent influence and interaction with NMDA receptors. MPEP, mPFC, PFC
53  2005 A reduced number of metabotropic glutamate subtype 5 receptors are associated with constitutive homer proteins in a mouse model of fragile X syndrome. FMRP, fraX, GluR, KO, SPMs
54  2005 Cyclohexenyl- and dehydropiperidinyl-alkynyl pyridines as potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists. ---
55  2005 Dipyridyl amides: potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists. ---
56  2005 Dipyridyl amines: potent metabotropic glutamate subtype 5 receptor antagonists. ---
57  2005 Functional interaction between mGlu 5 and NMDA receptors in a rat model of Parkinson's disease. MPEP
58  2005 Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice. KO
59  2005 Metabotropic glutamate 5 receptor blockade may attenuate cocaine self-administration by decreasing brain reward function in rats. ICSS
60  2005 Metabotropic glutamate receptor (mGluR5) antagonist MPEP attenuated cue- and schedule-induced reinstatement of nicotine self-administration behavior in rats. ---
61  2005 The effect of the mGlu5 receptor antagonist MPEP in rodent tests of anxiety and cognition: a comparison. CER, DMTP, MPEP
62  2005 Transient lower esophageal sphincter relaxations in dogs are inhibited by a metabotropic glutamate receptor 5 antagonist. MPEP
63  2004 2-(2-[3-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl) pyridine: a highly potent, orally active, metabotropic glutamate subtype 5 (mGlu5) receptor antagonist. ---
64  2004 3-[3-Fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]-4-methylpyridine: a highly potent and orally bioavailable metabotropic glutamate subtype 5 (mGlu5) receptor antagonist. ---
65  2004 5-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-2,3'-bipyridine: a highly potent, orally active metabotropic glutamate subtype 5 (mGlu5) receptor antagonist with anxiolytic activity. ---
66  2004 Discovery of highly potent, selective, orally bioavailable, metabotropic glutamate subtype 5 (mGlu5) receptor antagonists devoid of cytochrome P450 1A2 inhibitory activity. ---
67  2004 Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity. FPS
68  2004 Effects of adenosine A1, dopamine D1 and metabotropic glutamate 5 receptors-modulating agents on locomotion of the reserpinised rats. l-DOPA
69  2004 Metabotropic glutamate receptor 5 localized in the limbic forebrain is critical for the development of morphine-induced rewarding effect in mice. i.c.v, MPEP, PKCgamma
70  2004 The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in rodent models of anxiety. MPEP, MTEP
71  2003 Activation of metabotropic glutamate 5 and NMDA receptors underlies the induction of persistent bursting and associated long-lasting changes in CA3 recurrent connections. ---
72  2003 [3H]-methoxymethyl-MTEP and [3H]-methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor. ---
73  2001 Metabotropic glutamate receptor subtype 5 (mGlu5) and nociceptive function. I. Selective blockade of mGlu5 receptors in models of acute, persistent and chronic pain. MPEP